Abstract
The 2006 discovery of the process of RNA interference opened the door to application of this phenomenon for disease treatments. Short interfering RNA (siRNA) can be used to induce RNA interference, and this approach has generated much interest as a new type of nucleic acid-based drugs in humans and other mammals. However, despite the great potential of siRNA-based drugs in cancer therapy, some drawbacks of siRNAs, such as their instability in vivo and poor cellular uptake, remain unresolved. Here, we review the development of siRNA-based drugs targeting the human Bcl-xL gene, an anti-apoptotic factor overexpressed in many cancers, including prostate cancers. We also introduce a novel application of the biomaterial atelocollagen as a vehicle to functionally deliver tumor-specific siRNA molecules in nude mice. Here, we introduce an orthotopic tumor inoculation model in nude mice: the resulting orthotopic tumors more closely replicate the clinical conditions in humans—including the metastasis mode—than ectopic subcutaneously inoculated tumors.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Elbashir SM, Harborth J, Lendeckel W, Yalcin A, Weber K, Tuschl T (2001) Duplexes of 21-nucleotide RNAs mediate interference in cultured mammalian cells. Nature 411:494–498
Fire A, Xu S, Montgomery MK, Kostas SA, Driver SE, Mello CC (1998) Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature 391:806–811
Carpenter AE, Sabatini DM (2004) Systematic genome-wide screens of gene function. Nat Rev Genet 5:11–22
Zheng L, Liu J, Batalov S et al (2004) An approach to genomewide screens of expressed small interfering RNAs in mammalian cells. Proc Natl Acad Sci U S A 101:135–140
Karagiannis TC, El-Osta A (2004) Mechanism of RNA interference, in vivo and potential clinical applications. Cancer Biol Ther 3:1069–1074
Ryther RCC, Flynt AS, Phillips JA III, Patton JG (2005) siRNA therapeutics: big potential from small RNAs. Gene Ther 12:5–11
Mu P, Nagahara S, Makita N, Tarumi Y, Kadomatsu K, Takei Y (2009) Systemic delivery of siRNA specific to tumor mediated by atelocollagen: combined therapy using siRNA targeting Bcl-xL and cisplatin against prostate cancer. Int J Cancer 125:2978–2990
Boise LH, González-GarcĂa M, Postema CE, Ding L, Lindsten T, Turka LA, Mao X, Nuñez G, Thompson CB (1993) bcl-x, a bcl-2-related gene that functions as a dominant regulator of apoptotic cell death. Cell 74:597–608
Schott AF, Apel IJ, Nuñez G, Clarke MF (1995) Bcl-XL protects cancer cells from p53-mediated apoptosis. Oncogene 11:1389–1394
Yuan Y, Makita N, Cao D, Mihara K, Kadomatsu K, Takei Y (2015) Atelocollagen-mediated intravenous siRNA delivery specific to tumor tissues orthotopically xenografted in prostates of nude mice and its anticancer effects. Nucleic Acid Ther 25:85–94
Ochiya T, Takahama Y, Nagahara S, Sumita Y, Hisada A, Itoh H, Nagai Y, Terada M (1999) New delivery system for plasmid DNA in vivo using atelocollagen as a carrier material: the Minipellet. Nat Med 5:707–710
Takei Y, Kadomatsu K (2005) In vivo delivery technique of nucleic acid compounds using atelocollagen: its use in cancer therapeutics targeted at the heparin-binding growth factor midkine. Gene Ther Mol Biol 9:257–264
Fujimoto I, Takei Y (2014) Atelocollagen-mediated siRNA delivery: future promise for therapeutic application. Ther Deliv 5:369–371
Inaba S, Nagahara S, Makita N, Tarumi Y, Ishimoto T, Matsuo S, Kadomatsu K, Takei Y (2012) Atelocollagen-mediated systemic delivery prevents immunostimulatory adverse effects of siRNA in mammals. Mol Ther 20:356–366
Ishimoto T, Takei Y, Yuzawa Y, Hanai K, Nagahara S, Tarumi Y, Matsuo S, Kadomatsu K (2008) Downregulation of monocyte chemoattractant protein-1 involving short interfering RNA attenuates hapteninduced contact hypersensitivity. Mol Ther 16:387–395
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2019 Springer Science+Business Media, LLC, part of Springer Nature
About this protocol
Cite this protocol
Takei, Y. (2019). siRNA-Based Drug Targeting Human Bcl-xL Against Cancers. In: Dinesh Kumar, L. (eds) RNA Interference and Cancer Therapy. Methods in Molecular Biology, vol 1974. Humana, New York, NY. https://doi.org/10.1007/978-1-4939-9220-1_3
Download citation
DOI: https://doi.org/10.1007/978-1-4939-9220-1_3
Published:
Publisher Name: Humana, New York, NY
Print ISBN: 978-1-4939-9219-5
Online ISBN: 978-1-4939-9220-1
eBook Packages: Springer Protocols